SRSF9 Antibody

What is SRSF9 and what are its main biological functions?

SRSF9 (also known as SFRS9 or SRP30C) is a member of the serine/arginine (SR)-rich family of pre-mRNA splicing factors, which constitute part of the spliceosome. It plays a crucial role in constitutive splicing and can modulate the selection of alternative splice sites. Specifically, it has been shown to repress the splicing of MAPT/Tau exon 10. Beyond splicing regulation, SR proteins including SRSF9 are involved in mRNA export from the nucleus and in translation processes . Recent research has also implicated SRSF9 in regulating cassette exon splicing of Caspase-2 through interaction mechanisms .

What types of SRSF9 antibodies are available for research use?

There are several types of SRSF9 antibodies available for research applications:

• Mouse monoclonal antibodies (e.g., OTI5G7 clone)

• Rabbit polyclonal antibodies (e.g., 17926-1-AP)

Each type has specific characteristics and optimal applications:

What is the molecular structure and characteristics of SRSF9?

SRSF9 is a protein with a calculated molecular weight of approximately 25.4-26 kDa . It contains:

• An N-terminal RNA recognition motif (RRM) for binding RNA

• A glycine-rich region

• An internal region homologous to the RRM

• An RS domain rich in serine and arginine residues, which facilitates interaction with other proteins

The protein's structure enables its dual function in RNA binding and protein-protein interactions within the spliceosome complex.

What are the validated applications for SRSF9 antibodies?

Based on the available research data, SRSF9 antibodies have been validated for:

• Western Blot (WB): Detection of SRSF9 protein in cell and tissue lysates

• Immunohistochemistry (IHC-P): Visualization of SRSF9 in paraffin-embedded tissues

• ELISA: For some antibody products

The applications have been validated in multiple cell lines including HEK-293, HeLa, and HepG2 cells, as well as in various human tissues including breast, colon, kidney, lung, pancreas, prostate, and lymph nodes .

What is the optimal protocol for using SRSF9 antibodies in Western blotting?

For optimal Western blot results with SRSF9 antibodies:

• Sample preparation: Use fresh cell or tissue lysates; SRSF9 is expected at approximately 26 kDa

• Loading control: 10-20 μg of total protein per lane is typically sufficient

• Dilution:

  • For monoclonal antibodies: 1:2000

  • For polyclonal antibodies: 1:500-1:2000

• Detection: Standard secondary antibody protocols are applicable

• Controls: Include both positive (wild-type HEK-293T) and negative (SRSF9 knockout) controls when possible

How should I optimize immunohistochemistry protocols for SRSF9 detection?

For IHC-P applications:

• Tissue preparation: Standard paraffin embedding and sectioning protocols

• Antigen retrieval: For polyclonal antibodies, TE buffer pH 9.0 is recommended; alternatively, citrate buffer pH 6.0 can be used

• Antibody dilution:

  • Monoclonal antibodies: 1:150

  • Polyclonal antibodies: 1:500-1:2000

• Incubation: Overnight at 4°C is typically recommended

• Detection: Standard visualization protocols (DAB, etc.)

• Counterstaining: Hematoxylin for nuclear visualization

How can I validate the specificity of SRSF9 antibodies in my experimental system?

To ensure antibody specificity:

• Perform simultaneous analysis of:

  • Wild-type cells/tissues expressing SRSF9

  • SRSF9 knockout or knockdown models (if available)

  • Recombinant SRSF9 protein as a positive control

• Cross-validation approaches:

  • Use multiple antibodies targeting different epitopes of SRSF9

  • Complement protein detection with mRNA analysis (RT-PCR or RNA-seq)

  • Consider peptide competition assays to confirm specificity

• Molecular weight verification:

  • SRSF9 should be detected at approximately 26 kDa; any significant deviation may indicate non-specific binding or post-translational modifications

What experimental controls should I include when studying SRSF9 in cancer research?

Based on pan-cancer analysis studies of SRSF9 , recommended controls include:

• Tissue controls:

  • Matched normal adjacent tissue alongside tumor samples

  • Tissue microarrays containing multiple cancer types for comparative studies

• Cell line controls:

  • Normal epithelial cells corresponding to the cancer type

  • Cell lines with known SRSF9 expression levels

  • SRSF9 knockdown/knockout cell models

• Expression controls:

  • Analysis of related SR proteins (SRSF family members)

  • Assessment of downstream targets influenced by SRSF9 splicing activity

How can I design experiments to study the relationship between SRSF9 and tumor immunity?

Recent research has identified correlations between SRSF9 expression and tumor immunity markers . When designing such experiments:

• Consider a multi-platform approach:

  • Protein expression analysis (IHC, WB)

  • RNA expression and splicing analysis (RNA-seq)

  • Immune phenotyping (flow cytometry)

• Include analysis of:

  • Tumor mutation burden (TMB)

  • Microsatellite instability (MSI)

  • Immune checkpoint gene expression

  • Tumor microenvironment (TME) characteristics

  • Immune infiltrating cells

• Experimental models:

  • Patient-derived xenografts

  • Syngeneic mouse models for immune component analysis

  • Co-culture systems with immune cells and cancer cells with modulated SRSF9 expression

Why might I observe variable SRSF9 staining patterns across different tissues and cancers?

Variation in SRSF9 staining patterns can occur due to:

• Biological factors:

  • Tissue-specific expression patterns of SRSF9

  • Cancer-specific alterations in SRSF9 expression or localization

  • Correlation with tumor grade or stage (as observed in multiple cancer types)

• Technical considerations:

  • Fixation conditions affecting epitope accessibility

  • Antigen retrieval efficiency varying by tissue type

  • Variations in endogenous peroxidase activity

• Interpretation approach:

  • Compare with published SRSF9 expression data across tissues

  • Consider both intensity and subcellular localization (nuclear vs. cytoplasmic)

  • Correlate with other SR protein expression patterns

How should I interpret conflicting SRSF9 expression data between protein and mRNA levels?

When facing discrepancies between protein and mRNA expression:

• Consider post-transcriptional regulation:

  • SRSF9 itself is subject to alternative splicing

  • miRNA-mediated regulation may affect translation efficiency

  • Protein stability may vary under different cellular conditions

• Technical considerations:

  • Different detection sensitivities between antibody-based methods and RNA analysis

  • Antibody specificity for different SRSF9 isoforms

  • Sample preparation differences affecting RNA vs. protein preservation

• Validation approaches:

  • Employ multiple antibodies targeting different SRSF9 epitopes

  • Conduct parallel protein and RNA analysis from the same samples

  • Consider polysome profiling to assess translation efficiency

What are common troubleshooting issues with SRSF9 antibodies in Western blotting?

When troubleshooting Western blot problems:

• No signal:

  • Check antibody concentration (consider 1:500 dilution for initial optimization)

  • Verify sample preparation (nuclear extraction may improve detection)

  • Ensure transfer efficiency for proteins in the 26 kDa range

  • Consider extended exposure times for low expression samples

• Multiple bands:

  • Could indicate splice variants or post-translational modifications

  • Cross-reactivity with other SR proteins due to conserved domains

  • Sample degradation leading to proteolytic fragments

  • Non-specific binding requiring additional blocking optimization

• High background:

  • Increase blocking time or concentration

  • Reduce primary antibody concentration

  • Consider alternative blocking agents (milk vs. BSA)

  • Increase wash steps and duration

How can I effectively study SRSF9's role in alternative splicing regulation?

To investigate SRSF9's splicing regulatory functions:

• Experimental approaches:

  • RNA-seq following SRSF9 knockdown/overexpression to identify affected splice events

  • Minigene assays for specific target exons (e.g., MAPT/Tau exon 10)

  • CLIP-seq to identify direct RNA binding targets

  • In vitro splicing assays with purified components

• Target selection:

  • Focus on known SRSF9 targets like Caspase-2

  • Analyze cancer-specific splicing events potentially regulated by SRSF9

  • Investigate interaction with other splicing regulators

• Functional validation:

  • Mutational analysis of SRSF9 binding motifs in target RNAs

  • Structure-function studies separating RNA binding from protein interaction domains

  • Correlate splicing changes with phenotypic outcomes in cellular models

What methodologies can reveal SRSF9's potential role as a cancer biomarker?

Based on pan-cancer analysis findings , to investigate SRSF9 as a biomarker:

• Multi-cohort validation:

  • Analyze SRSF9 expression across large patient cohorts using tissue microarrays

  • Correlate with clinical outcomes (survival, treatment response)

  • Perform multivariate analysis with established biomarkers

• Mechanistic studies:

  • Identify cancer-relevant splice variants regulated by SRSF9

  • Investigate correlation with oncogenic signaling pathways

  • Examine relationship with tumor immune microenvironment components

• Translational approaches:

  • Develop standardized IHC scoring systems for SRSF9 expression

  • Evaluate SRSF9 in liquid biopsy samples (circulating tumor cells, exosomes)

  • Assess SRSF9-regulated splice variants in patient samples

How can I investigate the relationship between SRSF9 and immunotherapy response?

To explore SRSF9's potential role in immunotherapy:

• Correlation studies:

  • Analyze SRSF9 expression in pre- and post-treatment biopsies

  • Correlate with response to immune checkpoint inhibitors

  • Examine relationship with tumor mutation burden and microsatellite instability

• Functional studies:

  • Modulate SRSF9 expression in tumor models and assess immune infiltration

  • Investigate splicing of immune-related genes regulated by SRSF9

  • Analyze effect on antigen presentation and recognition

• Predictive modeling:

  • Integrate SRSF9 expression with other immune markers for response prediction

  • Develop and validate predictive algorithms incorporating SRSF9 status

  • Assess potential for patient stratification in immunotherapy trials